Janssen pharmaceuticals case study
Biochemical Profiling of PBMC
Partnership
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is a large pharmaceutical company known for developing innovative treatments. They’re responsible for research into a variety of diseases and highly recognize for their COVID-19 vaccine.
QurieGen collaborated with Janssen Pharmaceuticals to demonstrate the potential of QuRIEseq in studying immune responses.
Key findings
Problem: Understand MoA of stimuli in peripheral blood mononuclear cells
Result: Treatment with stimuli shows time-dependent, cell-(sub)type-specific changes in transcriptome and proteome landscape
Scientific impact: Prediction of co-stimulatory effects in a heterogeneous mixture of cells
Outcomes:
In this study, we demonstrated the potential of QuRIEseq for analyzing heterogeneous populations of primary cells, focusing on the entire population of peripheral blood mononuclear cells (PBMCs). Treatment with a stimulus revealed time-dependent, cell-(sub)type-specific changes in both the transcriptome and proteome landscapes.